{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:40:14Z","timestamp":1756183214352,"version":"3.44.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Combination therapy comprising ipilimumab and nivolumab is a safe and effective treatment for advanced renal cell carcinoma (RCC). However, its use in papillary RCC (pRCC) with an inferior vena cava (IVC) tumor thrombus extending to the right atrium has not been reported. Herein, we describe a case of pRCC with an IVC tumor thrombus extending to the right atrium and multiple metastases, which was effectively treated with combination therapy comprising ipilimumab and nivolumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 74-year-old man was diagnosed with pRCC based on a computed tomography-guided biopsy of a left renal tumor. The tumor extended to the right atrium and was accompanied by metastases to the pancreas, retroperitoneum, lymph nodes, bones, and lungs (cT3cN2M1). Based on the International Metastatic Database Consortium risk classification, the case was categorized as poor risk. Therefore, combination therapy comprising ipilimumab and nivolumab was initiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine months after initiating treatment, all metastases had disappeared, enabling open cytoreductive nephrectomy that had been deferred. Histopathological analysis revealed necrosis in most of the tumor tissue, with no viable cells in the primary tumor and IVC tumor thrombus. At 24 months postoperatively, the patient remained recurrence-free.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This case highlights the potential efficacy of preoperative combination therapy with ipilimumab and nivolumab in advanced pRCC with IVC tumor thrombus and distant metastases. The treatment achieved a complete response and allowed successful surgical resection, suggesting its potential as a viable option in similar cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1547387","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:12:45Z","timestamp":1756181565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases"],"prefix":"10.3389","volume":"15","author":[{"given":"Chika","family":"Nagahisa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kobari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174353","article-title":"Advanced non-clear cell renal cell carcinoma treatments and survival: A real-world single-centre experience","volume":"15","author":"Bimbatti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jaccao.2022.05.006","article-title":"Prevalence, treatment, and prognosis of tumor thrombi in renal cell carcinoma","volume":"4","author":"Haddad","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15128","article-title":"Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: real-world data from a Japanese multicenter retrospective study","volume":"30","author":"Izumi","year":"2023","journal-title":"Int J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.1987.tb04832.x","article-title":"Surgical treatment of renal cancer with vena cava extension","volume":"59","author":"Neves","year":"1987","journal-title":"Br J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.08.012","article-title":"Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma","volume":"37","author":"Singla","year":"2019","journal-title":"Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.04.013","article-title":"Papillary renal cell carcinoma: Review [Review","volume":"39","author":"Mendhiratta","year":"2021","journal-title":"Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001794","article-title":"Characterizing tumor thrombus arising from non\u2013clear cell renal cell carcinoma","volume":"46","author":"Williamson","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12123","article-title":"Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: single-center experience","volume":"20","author":"Kondo","year":"2013","journal-title":"Int J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.039","article-title":"Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup","volume":"177","author":"Haferkamp","year":"2007","journal-title":"J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1515\/oncologie-2024-0246","article-title":"Radiotherapy directed to inferior vena cava tumor thrombus among patients with renal cell carcinoma: an illustrative case and review of the literature","volume":"26","author":"Zagardo","year":"2024","journal-title":"Oncologie"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.11.012","article-title":"Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma","volume":"18","author":"Gupta","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e003844","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1547387\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:12:46Z","timestamp":1756181566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1547387\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":17,"alternative-id":["10.3389\/fonc.2025.1547387"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1547387","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1547387"}}